Cisplatin plus irinotecan versus cisplatin plus gemcitabine in the treatment of advanced or metastatic gallbladder or biliary tract cancer: Results of a randomized phase II trial (NCT01859728)- the Gambit trial

被引：0
|
作者：
dos Santos, Lucas Vieira
Faria Pinto, Gustavo Sanches
Souto Ferraz, Mauricio Wagner
Bragagnoli, Arinilda
Santos, Florinda
Haddad, Sarah
Barros, Ana
Cordeiro Dias, Isadora Clarissa
Lima, Joao Paulo S. N.
Abdalla, Kathia C.
机构：
[1] Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil
[2] Barretos Canc Hosp, Barretos, Brazil
[3] Barretos Canc Ctr, Barretos, Brazil
[4] Hosp Canc Barretos, Barretos, Brazil
[5] AC Camargo Canc Ctr, Sao Paulo, Brazil
[6] Fundacao Fac Med Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529
引用
收藏
页数：2
相关论文
共 50 条
  • [41] 3.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Randall Brand
    中国肿瘤临床, 2010, (12) : 726 - 726
  • [42] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    Stemmler, H. J.
    diGioia, D.
    Freier, W.
    Tessen, H. W.
    Gitsch, G.
    Jonat, W.
    Brugger, W.
    Kettner, E.
    Abenhardt, W.
    Tesch, H.
    Hurtz, H. J.
    Roesel, S.
    Brudler, O.
    Heinemann, V.
    BRITISH JOURNAL OF CANCER, 2011, 104 (07) : 1071 - 1078
  • [43] Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
    Morizane, C.
    Okusaka, T.
    Mizusawa, J.
    Katayama, H.
    Ueno, M.
    Ikeda, M.
    Ozaka, M.
    Okano, N.
    Sugimori, K.
    Fukutomi, A.
    Hara, H.
    Mizuno, N.
    Yanagimoto, H.
    Wada, K.
    Tobimatsu, K.
    Yane, K.
    Nakamori, S.
    Yamaguchi, H.
    Asagi, A.
    Yukisawa, S.
    Kojima, Y.
    Kawabe, K.
    Kawamoto, Y.
    Sugimoto, R.
    Iwai, T.
    Nakamura, K.
    Miyakawa, H.
    Yamashita, T.
    Hosokawa, A.
    Ioka, T.
    Kato, N.
    Shioji, K.
    Shimizu, K.
    Nakagohri, T.
    Kamata, K.
    Ishii, H.
    Furuse, J.
    ANNALS OF ONCOLOGY, 2019, 30 (12) : 1950 - 1958
  • [44] Neoadjuvant durvalumab plus gemcitabine and cisplatin (D plus GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
    Yoo, C.
    Park, J. O.
    Kim, K-P.
    Hyung, J.
    Ryoo, B-Y.
    Hong, J. Y.
    Shin, S. H.
    Song, T. J.
    Oh, D.
    Lee, W.
    Kwak, B. J.
    Lee, J. H.
    Hwang, D. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S216 - S216
  • [45] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    H J Stemmler
    D diGioia
    W Freier
    H W Tessen
    G Gitsch
    W Jonat
    W Brugger
    E Kettner
    W Abenhardt
    H Tesch
    H J Hurtz
    S Rösel
    O Brudler
    V Heinemann
    British Journal of Cancer, 2011, 104 : 1071 - 1078
  • [46] Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study
    Woo, Sang Myung
    Lee, Woo Jin
    Kim, Ji Hun
    Kim, Dong Hwan
    Han, Sung-Sik
    Park, Sang-Jae
    Kim, Tae Hyun
    Lee, Ju Hee
    Koh, Young Hwan
    Hong, Eun Kyung
    CHEMOTHERAPY, 2013, 59 (03) : 232 - 238
  • [47] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial
    Georgoulias, V.
    Ardavanis, A.
    Tsiafaki, X.
    Agelidou, A.
    Syrigos, K.
    Polyzos, A.
    Kakolyris, S.
    Kouroussis, Ch
    Androulakis, N.
    Chatzidaki, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 169 - 169
  • [48] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
    Georgoulias, V
    Ardavanis, A
    Tsiafaki, X
    Agelidou, A
    Mixalopoulou, P
    Anagnostopoulou, O
    Ziotopoulos, P
    Toubis, M
    Syrigos, K
    Samaras, N
    Polyzos, A
    Christou, A
    Kakolyris, S
    Kouroussis, C
    Androulakis, N
    Samonis, G
    Chatzidaki, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2937 - 2945
  • [49] A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II)
    Nishikawa, Kazuhiro
    Tsuburaya, Akira
    Yoshikawa, Takaki
    Kobayashi, Michiya
    Kawada, Junji
    Fukushima, Ryoji
    Matsui, Takanori
    Tanabe, Kazuaki
    Yamaguchi, Kazuya
    Yoshino, Shigefumi
    Takahashi, Masazumi
    Hirabayashi, Naoki
    Sato, Seiji
    Nemoto, Hiroshi
    Rino, Yasushi
    Nakajima, Junta
    Aoyama, Toru
    Miyagi, Yohei
    Oriuchi, Noboru
    Yamaguchi, Kensei
    Miyashita, Yumi
    Morita, Satoshi
    Sakamoto, Junichi
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 220 - 228
  • [50] Randomized phase II trial of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) for advanced gastric cancer
    Shin, D.
    Lee, S.
    Park, S.
    Park, J.
    Cho, E.
    Lee, J.
    Lee, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345